Novartis/ThromboGenics' jet off with EU go-ahead and US launch for Jetrea
This article was originally published in Scrip
Executive Summary
The EU's CHMP has granted a positive opinion for marketing to Novartis/ ThromboGenics' Jetrea (ocriplasmin), the first drug for treating the sight-threatening eye disorder, vitreomacular traction. The go-ahead comes just days after ThromboGenics launched the product in the US on 14 January, its first market, following FDA approval in October (scripintelligence.com, 4 January 2013).